» Articles » PMID: 38110438

Transcriptional Profiles of Pulmonary Artery Endothelial Cells in Pulmonary Hypertension

Abstract

Pulmonary arterial hypertension (PAH) is characterized by endothelial cell (EC) dysfunction. There are no data from living patients to inform whether differential gene expression of pulmonary artery ECs (PAECs) can discern disease subtypes, progression and pathogenesis. We aimed to further validate our previously described method to propagate ECs from right heart catheter (RHC) balloon tips and to perform additional PAEC phenotyping. We performed bulk RNA sequencing of PAECs from RHC balloons. Using unsupervised dimensionality reduction and clustering we compared transcriptional signatures from PAH to controls and other forms of pulmonary hypertension. Select PAEC samples underwent single cell and population growth characterization and anoikis quantification. Fifty-four specimens were analyzed from 49 subjects. The transcriptome appeared stable over limited passages. Six genes involved in sex steroid signaling, metabolism, and oncogenesis were significantly upregulated in PAH subjects as compared to controls. Genes regulating BMP and Wnt signaling, oxidative stress and cellular metabolism were differentially expressed in PAH subjects. Changes in gene expression tracked with clinical events in PAH subjects with serial samples over time. Functional assays demonstrated enhanced replication competency and anoikis resistance. Our findings recapitulate fundamental biological processes of PAH and provide new evidence of a cancer-like phenotype in ECs from the central vasculature of PAH patients. This "cell biopsy" method may provide insight into patient and lung EC heterogeneity to advance precision medicine approaches in PAH.

Citing Articles

Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).

Forbes L, Bauer N, Bhadra A, Bogaard H, Choudhary G, Goss K Pulm Circ. 2025; 15(1):e70027.

PMID: 39749110 PMC: 11693987. DOI: 10.1002/pul2.70027.


Characteristic disease defects in circulating endothelial cells isolated from patients with pulmonary arterial hypertension.

Aulak K, Mavarakis L, Tian L, Paul D, Comhair S, Dweik R PLoS One. 2024; 19(10):e0312535.

PMID: 39466801 PMC: 11516004. DOI: 10.1371/journal.pone.0312535.


Synergistic Effects of Weight Loss and Catheter Ablation: Can microRNAs Serve as Predictive Biomarkers for the Prevention of Atrial Fibrillation Recurrence?.

Forster C, Kunzel S, Shityakov S, Stavrakis S Int J Mol Sci. 2024; 25(9).

PMID: 38731908 PMC: 11083177. DOI: 10.3390/ijms25094689.

References
1.
Culley M, Chan S . Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest. 2018; 128(9):3704-3715. PMC: 6118596. DOI: 10.1172/JCI120847. View

2.
Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

3.
Yan Z, Delannoy M, Ling C, Daee D, Osman F, Muniandy P . A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. Mol Cell. 2010; 37(6):865-78. PMC: 2847587. DOI: 10.1016/j.molcel.2010.01.039. View

4.
Budhiraja R, Tuder R, Hassoun P . Endothelial dysfunction in pulmonary hypertension. Circulation. 2004; 109(2):159-65. DOI: 10.1161/01.CIR.0000102381.57477.50. View

5.
Xu W, Erzurum S . Endothelial cell energy metabolism, proliferation, and apoptosis in pulmonary hypertension. Compr Physiol. 2013; 1(1):357-72. PMC: 6467053. DOI: 10.1002/cphy.c090005. View